For the year ending 2025-12-31, SION had $20,664K increase in cash & cash equivalents over the period. -$66,674K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -75,268 |
| Stock-based compensation expense | 12,066 |
| Non-cash operating lease expense | 1,962 |
| Amortization of discount on marketable securities | 3,052 |
| Non-cash expense related to ipr&d acquisition | 0 |
| Depreciation expense | 647 |
| Prepaid expenses and other current assets | 2,082 |
| Accounts payable | -417 |
| Accrued expenses and other current liabilities | 1,975 |
| Operating lease liability | -2,128 |
| Other assets | 0 |
| Net cash used in operating activities | -66,297 |
| Purchases of property and equipment | 377 |
| Purchases of marketable securities | 325,025 |
| Maturities of marketable securities | 206,653 |
| Net cash used in investing activities | -118,749 |
| Proceeds from initial public offering, net of underwriter discounts, commissions and offering costs paid during the period | 202,071 |
| Proceeds from issuance of series c convertible preferred stock, net of issuance costs | 0 |
| Payment of deferred offering costs | 0 |
| Exercise of common stock options | 3,639 |
| Net cash provided by financing activities | 205,710 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 20,664 |
| Cash, cash equivalents and restricted cash at beginning of period | 38,750 |
| Cash, cash equivalents and restricted cash at end of period | 59,414 |
Sionna Therapeutics, Inc. (SION)
Sionna Therapeutics, Inc. (SION)